Essential Premium

Biopharma Funds’ Rally Rides on Narrow Leadership

Big moves in a handful of biotech stocks powered April gains, but most funds continue to lag indexes in 2026.

Quantum Computing Is Coming — But Asset Owners Are Asking the Wrong Question

As with AI, the real risk isn’t adoption — it’s failing to recognize which quantum threats demand action now and which can wait.

Sponsored

Why Geopolitical Risk is Fueling the Dollar’s Surge

Icahn’s Hedge Fund Stumbles Again as Shorts Backfire

The legendary investor’s private hedge fund is back in the red.

Related Content

Your CapEx Is My Opportunity: The Benchmark Arbitrage of the AI Buildout

Why Biotech Struggles to Finish What It Starts

Julie Segal

Private Markets’ New Tension: When Retail and Institutional Investors Collide

Julie Segal

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram